Choroidal Neovascularization Market
Report ID: SQMIG35H2404
Report ID: SQMIG35H2404
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2404 |
Region:
Global |
Published Date: January, 2025
Pages:
186
|Tables:
119
|Figures:
71
Global Choroidal Neovascularization Market size was valued at USD 6.3 billion in 2024 and is poised to grow from USD 6.7 billion in 2025 to USD 10.92 billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).
Rising prevalence of age-related diseases, increasing geriatric population, and technological advancements in diagnosis and treatment drive the growth of the choroidal neovascularization market.
With increasingly aging populations worldwide, there is an observed spike in ocular disorders associated with aging, specifically conditions that tend to result in choroidal neovascularization, like macular degeneration. All this leads to increased needs for early diagnosis and proper treatment methods among the burgeoning elderly population, which is most prone to such degenerative eventualities. Enhanced imaging technology and therapeutic innovations not only have improved the clinical outcomes, but the entire healthcare response to retinal disease. Today, the trend towards democratizing access to new care and promoting active patient involvement in their treatment is driving choroidal neovascularization market growth in this particular case.
In the face of healthcare needs emerging from limited access and poor medical infrastructure, healthcare professionals and industry players are constantly called to innovate and invest in growth. The high treatment cost challenge has awakened the choroidal neovascularization industry towards seeking more effective therapies and alternative modes of care delivery. The combined effect of such barriers further points out market imbalances and encourages precise market approaches focused on enhancing availability and affordability for the populations concerned.
How is AI Transforming the Choroidal Neovascularization Industry?
Artificial intelligence is increasingly transforming the market for choroidal neovascularization through the adoption of advanced tools that further improve diagnostic accuracy as well as therapeutic decision-making. With deep learning computer algorithms able to decipher complex imaging data, clinicians gain faster and more accurate detection of retinal abnormalities, eventually leading to early intervention and individualized treatment plans. The incorporation of predictive analytics enables healthcare professionals to foretell disease progression, thus facilitating a more anticipatory approach in patient management. As these technologies become integrated in clinical work processes, the choroidal neovascularization market analysis exhibits a trend toward increased efficiency, enhanced patient outcomes, and increased standards of care.
Market snapshot - 2026-2033
Global Market Size
USD 6.08 Billion
Largest Segment
Intravitreal
Fastest Growth
Intravenous
Growth Rate
6.5% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Choroidal Neovascularization Market is segmented by Disease Type, Treatment Type, Route of Administration, End User, Age Group and region. Based on Disease Type, the market is segmented into Age-related Macular Degeneration, Pathologic Myopia, Ocular Histoplasmosis and Other Retinal Disorders. Based on Treatment Type, the market is segmented into Anti-VEGF Therapy, Photodynamic Therapy and Corticosteroids. Based on Route of Administration, the market is segmented into Intravitreal Injection, Oral and Others. Based on End User, the market is segmented into Hospitals, Ophthalmology Clinics and Ambulatory Surgical Centers. Based on Age Group, the market is segmented into Adult and Geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
How Are Intravitreal Injections Improving CNV Treatment Outcomes?
The intravitreal category has taken most of the choroidal neovascularization market strategies, because of its ability to directly deliver medicines against anti-VEGF agents into the eyeball. For conditions such as wet age-related macular degeneration (AMD), this method spells fast and effective treatment. Indeed, on a global level, intravitreal injections have been the most popular means of CNV treatment. Clinically, they have been used in combination with ranibizumab and aflibercept or other similar medications to block their inappropriate growth.
On the contrary, the intravenous category is anticipated to have the highest choroidal neovascularization market share. Long-acting implants and new systemic treatments are being developed, which may reduce the necessity for an injection on a repetitive basis. Finally, this might keep the option of having intravenous alternatives on the rise in the medium to long term based on promising new findings regarding gene treatments and sustained-release anti-VEGF systems.
How Do Hospitals Support High Adoption of Intravitreal Therapies?
According to the choroidal neovascularization market analysis, the hospitals category dominated the market, offering varieties of treatment and diagnosis. Administrative management comprises intraocular anti-VEGF injections by specialists in sterile working conditions. Therefore, patients suffering from CNV due to age-related macular degeneration (AMD) and other conditions are primarily treated in hospital ophthalmology departments. The specialized treatment of all neovascularization therapies by hospitals coupled with an extremely sophisticated optical coherence tomography (OCT) imaging facility allows for such extensive applications of CNV treatments.
Whereas the ophthalmology clinics category is anticipated to grow significantly during the projection period. This is due to higher application of anti-VEGF treatment protocols and imaging technologies in more increasingly specialized outpatient centers. Increased patient demand for outpatient care adds favorably to the workflow of this expansion.
To get detailed segments analysis, Request a Free Sample Report
What Makes North America a Leader in the Choroidal Neovascularization Market?
North America's dominance in the market for choroidal neovascularization is characterized by its sophisticated healthcare infrastructures, high disease awareness of retinal conditions, and rapid uptake of new treatments. A merger of these attributes has led to a well-defined, though yet evolving, region for changes in the choroidal neovascularization market statistics determinations. The region boasts both strong research and development efforts and relatively stringent reimbursement policies, along with very much more comprehensive access to advance diagnostics and therapeutic options.
Choroidal Neovascularization Market in the United States
High reputation for clinical quality, extensive healthcare infrastructure, and continued investment in cutting-edge therapies position the United States as a leading force in the choroidal neovascularization market. One-of-a-kind access to high-tech diagnostics and new therapy ensures early detection and effective intervention for patients. This kind of environment consistently drives revenues of the choroidal neovascularization market and bears testimony to advancement at the intersection of research, delivery of care, and patient outcomes.
Choroidal Neovascularization Market in Canada
In Canada, the choroidal neovascularization market regional outlook is supported by a well-structured public healthcare system and growing awareness of age-related eye conditions. Access to advanced diagnostic technologies and a commitment to early intervention to enhance patient outcomes. Efforts in improving treatment accessibility and ongoing research initiatives contribute significantly to choroidal neovascularization market strategies across the Canadian medical landscape.
What Makes Asia Pacific the Fastest-Growing Region in the Choroidal Neovascularization Market?
The dynamic increase in the resources allocated to healthcare, coupled with heightened awareness among the public and increased accessibility to diagnostics technology, positions Asia Pacific as the fast-emerging market in choroidal neovascularization. Sudden demographic changes, particularly by a burgeoning older adult population, act as the main reason for the increased demand for sophisticated ophthalmic care. Growing government investment and changing preventive tactics are key drivers of choroidal neovascularization market forecast projections that push the region to create its momentum.
Choroidal Neovascularization Market in Japan
In Japan, an increasingly aging population and increasing prevalence of retinal diseases have placed the nation as a prime focus in the choroidal neovascularization market. Latest in therapy and imaging technology fuse into the already isolated but well-established healthcare infrastructure, getting these technologies to use the newest methods for diagnosis and treatment. The current drug development and awareness among patients heavily define the market insight into choroidal neovascularization in Japan, which thus ensures a flow of constant innovation and improvement.
Choroidal Neovascularization Market in South Korea
South Korea's allegiance to medical innovation and robust healthcare provision has established it as a leading force in the progressive choroidal neovascularization market. With enhanced knowledge of retinal diseases and the availability of advanced diagnostic equipment, patients enjoy prompt and precise treatment. This advancement is increasingly evident in choroidal neovascularization industry trends, highlighting South Korea's commitment to progressing ophthalmic care.
How Is the Choroidal Neovascularization Market Evolving in Europe?
In Europe, enhanced diagnostic technologies, customized treatments, and a robust co-operative ecosystem of industry and academia are together improving the care of choroidal neovascularization. The continent is witnessing long-term advances in retinal therapy awareness and accessibility, driven by the rising prevalence of age-related eye diseases and active research activities. Present choroidal neovascularization market regional forecast, reflecting increasing use of minimally invasive therapies and innovative drug delivery technologies to treat emerging clinical demands.
Choroidal Neovascularization Market in Germany
Germany is unique in Europe for having a comprehensive health system and well-established position in the use of advanced ophthalmology, which underpins a strong framework for the diagnosis and treatment of choroidal neovascularization. It is with rare heavy emphasis placed on early detection and patient entry into innovative therapy that pharmaceutical and biotechnology leaders have taken part in ongoing research. This spirit of development is very much represented on the choroidal neovascularization market share analysis, with Germany being considered center stage in clinical innovation and in the adoption of new standards of sight care.
Choroidal Neovascularization Market in France
France further develops its lead in the choroidal neovascularization market through public health programs, extensive availability of specialist care, and ongoing investment in medical research. With increasing awareness of vision loss due to age, early intervention schemes are increasingly prominent. These collaborative healthcare measures are seen through choroidal neovascularization market analysis, which indicates France's focus on advancing retinal care solutions.
Choroidal Neovascularization Market in the United Kingdom
The United Kingdom illustrates excellent retinal disease care with good incorporation of advanced diagnostic and therapeutic technologies. Multidisciplinary research collaborations and affordable specialist care lead to timely intervention and better clinical outcomes for patients. Age-related eye conditions are becoming increasingly common, and investments continue to be made into research and healthcare infrastructure. All these factors ensure that the UK remains a driver for developing retinal health solutions in the rest of Europe and in the choroidal neovascularization market share.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Choroidal Neovascularization Market Drivers
Rising Prevalence of Age-Related Diseases
Technological Advancements in Diagnosis and Treatment
Choroidal Neovascularization Market Restraints
Limited Healthcare Access & Poor Infrastructure
High Cost of Treatment
Request Free Customization of this report to help us to meet your business objectives.
Within the choroidal neovascularization market, the increasing need for affordable and available treatment, coupled with technology developments in the medical field occurring at a frenetic pace, has heightened competition among major players. Companies in the market for the development of new diagnostic tools, extended therapy options, and patient-centric treatment strategies are well positioned to adapt to the ever-evolving clinical needs and strengthen their choroidal neovascularization market share in this dynamic healthcare environment.
Several startups are entering the choroidal neovascularization market, driven by increasing demand for sophisticated eye care and novel technologies. Top-notch innovators are transforming the choroidal neovascularization market’s future with niche solutions. Key startups are listed below.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the choroidal neovascularization market is growing significantly, driven by the expanding demand for affordable treatments, increased applications of cutting-edge diagnostics, and accelerating technological advances in the field of ophthalmology. However, the growth of the market is threatened by low awareness and poor healthcare infrastructure, particularly in low-income regions. The developed countries of North America dominate the market, supported by substantial investment in medical development. In the future, the establishment of affordable, patient-focused therapies will be a shaping trend determining the course of this specialty healthcare discipline.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 6.3 billion |
| Market size value in 2033 | USD 10.92 billion |
| Growth Rate | 6.3% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Choroidal Neovascularization Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Choroidal Neovascularization Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Choroidal Neovascularization Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Choroidal Neovascularization Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Choroidal Neovascularization Market size was valued at USD 6.08 Billion in 2023 and is poised to grow from USD 6.50 Billion in 2024 to USD 10.77 Billion by 2032, growing at a CAGR of 6.5% during the market forecast period (2025-2032).
Within the choroidal neovascularization market, the increasing need for affordable and available treatment, coupled with technology developments in the medical field occurring at a frenetic pace, has heightened competition among major players. Companies in the market for the development of new diagnostic tools, extended therapy options, and patient-centric treatment strategies are well positioned to adapt to the ever-evolving clinical needs and strengthen their choroidal neovascularization market share in this dynamic healthcare environment. 'Kriya Therapeutics: Founded in 2019, Fraser Wright, Shankar Ramaswamy, and Roger Jeffs. Kriya Therapeutics is an interesting start-up in the field of choroidal neovascularization committed to developing innovative gene therapy platforms for retinal diseases. The company uses sophisticated delivery technologies to manufacture durable and effective therapies that minimize the burden on patients. Its visionary approach creates a good fit with shifting market trends, making Kriya Therapeutics a primary driver of the future of targeted and tailored care for patients with neovascular eye diseases.', 'Exegenesis Bio: Established in 2019 by Zhenhua Wu. Exegenesis Bio has an exceptional place in the choroidal neovascularization market because it aims to build next-generation gene therapy solutions to treat ophthalmic diseases. The company puts a high emphasis on delivering novel delivery platforms and cutting-edge biotechnologies that can develop therapies designed to provide long-term benefits to patients with retinal vascular disorders. This direction places Exegenesis Bio at the forefront of choroidal neovascularization market research and will allow the company to deliver innovative care and set future standards in the industry.', 'Pfizer', 'Bayer AG', 'Novartis AG', 'AstraZeneca', 'Promedior Inc', 'Bausch Health', 'Endo International', 'Gilead Sciences Inc', 'Regeneron Pharmaceuticals Inc', 'Teva Pharmaceutical Industries Ltd', 'Sun Pharmaceutical Industries Ltd', 'Sanwa Kagaku Kenkyusho Co. Ltd.'
A consistent rise in age-related disorders, especially ocular, is radically realigning the dynamics of retinal healthcare. Due to this trend, there will be heightened risk for more complex disorders, such as choroidal neovascularization, thus increasing demand for precise diagnosis and targeted therapies. These changes are expected to impact the choroidal neovascularization market size and stimulate the advancement of clinical and investment-related activities related to new-age solutions for ocular care.
Advances in Anti-VEGF Therapies: With significant advancements in anti-VEGF treatment, the treatment patterns in the diseased Choroidal neovascularization market are changed. Such advances include longer-acting formulations and easier delivery systems that require fewer clinic visits. With increasing consistency in results and satisfaction from patients, among the trend changes seen in the choroidal neovascularization, development types are always influencing these trends; in fact, they mirror the importance of continuous biopharmaceutical R&D efforts.
What Makes North America a Leader in the Choroidal Neovascularization Market?
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
